393. Long-Acting Injectable Cabotegravir and Rilpivirine in the Aging HIV Population: Insights from the RELATIVITY Cohort
Jesús Troya, C. Busca, María José Galindo, María Lagarde et autres
Abstract Background Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) has become a standard treatment option for people living with HIV (PLWH), offering high efficacy, safety, and convenience. However, data from clinical trials and real-world cohorts involving people over 60 - an important …
es, us (code pays fourni par la source)